Inflammation in type 2 diabetes and associated disease

Published on February 27, 2022   27 min

Other Talks in the Series: Diabetes in Perspective

0:00
My name is Marc Donath. I'm an endocrinologist at the University Hospital in Basel, doing research and working in the clinic. My focus is on inflammation in patients with Type 2 Diabetes. This is the topic of today, focusing on inflammation in the pathophysiology and therapy of Type 2 Diabetes and associated disease.
0:26
What we described 20 years ago is that glucose induces IL-1β. We described that first in an animal model of diabetes, Psammomys obesus, which we put on a high energy diet. By doing so, IL-1β was increased. But then we treated the animal with phlorizin, which is an SGLT inhibitor. Just by doing so, IL-1β decreased. This proves, in vivo, that glucose induces IL-1β, and that one of the mechanisms of this SGLT2 inhibitor, which are drugs that induce glucosuria, meaning that the glucose goes into the urine, could be that it decreases the inflammation. But what is important with this talk is to realize this principle that glucose or metabolic stress can induce IL-1β. We come back to this concept, which is a general concept, in the context of what we call immunometabolism.
1:34
Beyond this cytokine, we went on to observe that in the islet of patients with Type 2 Diabetes, there is a real inflammation. Not just a few cytokines, but also immune cells, as you can see here on the right side of my presentation. We had some difficulty in having these concepts accepted, that is that there is an inflammation in islets of patients with Type 2 Diabetes. We made a lot of effort in this original publication to bring convincing data and fortunately, in the meantime, many others have confirmed these data.
Hide

Inflammation in type 2 diabetes and associated disease

Embed in course/own notes